# Molecularly Tailored Therapy in Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07802418/  
OnCo record `nct07802418` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Herlev Hospital, not yet recruiting.

## Summary

Molecularly Tailored Therapy in Advanced Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT07802418 by Herlev Hospital, with a registry enrolment figure of 1200 participants, started 2026-10 and due to reach its primary completion in 2031-06. Interventions recorded: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy; Arm 3: Standard-of-Care Observational Cohort. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival in Randomized Participants. Sites: Denmark. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: TAILOR-PANC
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07802418
- Phase: 2
- Setting: TAILOR-PANC: Molecularly Tailored Therapy Versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)
- Sponsor: Herlev Hospital
- Enrolled: 1200

## Sources

- ClinicalTrials.gov NCT07802418: https://clinicaltrials.gov/study/NCT07802418

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07802418.json